PSA Doubling Time (PSADT) Calculator

ورودی‌های بالینی بیمار

حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL

حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days

حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL

حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days

حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL

حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days

حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL

حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days

حداقل ۰.۰۱ — حداکثر ۱۰۰۰۰ • واحد: ng/mL

حداقل ۰ — حداکثر ۱۰۰۰۰ • واحد: days

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
psa doubling time
—months
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very High Risk0–3
  • High Risk3–6
  • Intermediate Risk6–12
  • Low Risk12–36
Direct Clinical Answer

The PSA Doubling Time (PSADT) Calculator calculates calculating PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. Key inputs include psa 1. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.

Clinical Indication

The PSA Doubling Time (PSADT) Calculator is indicated for bedside clinical practice to support Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Not applicable for initial prostate cancer screening or untreated patients.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Used only for patients with biochemical recurrence after treatment.

Formula & Variables:

PSADT = ln(2) / slope, where slope is derived from linear regression of ln(PSA) vs time

Input Parameters

NameTypeRequiredDescription
psa_1floatYesFirst PSA measurement in ng/mL(ng/mL)
days_1integerYesDays from baseline for first PSA measurement(days)
psa_2floatYesSecond PSA measurement in ng/mL(ng/mL)
days_2integerYesDays from baseline for second PSA measurement(days)
psa_3floatNoThird PSA measurement in ng/mL (optional)(ng/mL)
days_3integerNoDays from baseline for third PSA measurement (optional)(days)
psa_4floatNoFourth PSA measurement in ng/mL (optional)(ng/mL)
days_4integerNoDays from baseline for fourth PSA measurement (optional)(days)
psa_5floatNoFifth PSA measurement in ng/mL (optional)(ng/mL)
days_5integerNoDays from baseline for fifth PSA measurement (optional)(days)

Score Interpretation & Guidance

RangeStageDescription
0–3Very High RiskRapid PSA progression
3–6High RiskFast PSA progression
6–12Intermediate RiskModerate PSA progression
12–36Low RiskSlow PSA progression
36–1000Very Low RiskVery slow PSA progression

Evidence-Based References (EBM)

  • D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95(18):1376-83. doi: 10.1093/jnci/djg043.DOI: 10.1093/jnci/djg043
  • Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433-9. doi: 10.1001/jama.294.4.433.DOI: 10.1001/jama.294.4.433
  • Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7. doi: 10.1001/jama.281.17.1591.DOI: 10.1001/jama.281.17.1591
  • Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23(28):6992-8. doi: 10.1200/JCO.2005.01.2906.DOI: 10.1200/JCO.2005.01.2906

Related calculators